

Nouveau Biosciences Appoints Keith M. McGahan as Chief Legal Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering next-generation nanomedicine and targeted oncology therapeutics, today announced the appointment of Keith M. McGahan as Chief Legal Officer.

Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track record in corporate governance, compliance, and regulatory strategy. He most recently served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Spectrum Pharmaceuticals (NASDAQ: SPPI), where he guided the company through significant corporate milestones, culminating in its successful acquisition in 2023.

Earlier in his career, Mr. McGahan held senior legal and compliance positions at Avanir Pharmaceuticals and Johnson & Johnson, where he led global compliance initiatives and provided strategic legal oversight for innovative therapeutic portfolios. He also served in the U.S. Navy healthcare system as General Counsel and Chief Compliance Officer at the Naval Hospital Camp Pendleton and as Assistant General Counsel to the Navy Surgeon General.

“We are thrilled to welcome Keith to the executive leadership team,” said Owen A. O’Connor, M.D., Ph.D., Chief Executive Officer and Chairman of Nouveau Biosciences. “His deep expertise in legal strategy, compliance, and corporate governance will be instrumental as Nouveau advances its proprietary discovery technologies leading to targeted nanotherapeutics for cancer through clinical development and prepares for strategic partnerships.”

As Chief Legal Officer, Mr. McGahan will oversee all legal, compliance, and governance functions at Nouveau Biosciences. He will play a key role in shaping the company’s

regulatory pathway, strengthening its intellectual property portfolio, and supporting strategic collaborations.

“I am honored to join Nouveau Biosciences at such a pivotal stage in its growth,” said Keith M. McGahan. “The company’s drug discovery platform has the potential to transform how cancer is treated, and I look forward to supporting its mission to deliver safer, more effective therapies to patients worldwide.”

Mr. McGahan holds a Juris Doctor (J.D.), a Master of Laws (LL.M.) in Taxation, and a Master of Business Administration (MBA) in International Business. He is also a Certified Compliance & Ethics Professional (CCEP) and a graduate of the Healthcare Compliance Certification Program at Seton Hall Law School.

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company’s lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

Media Contact

Petrina Whyte

media@nouveaubiosciences.com